International Journal of Chemical Studies

P-ISSN: 2349–8528 E-ISSN: 2321–4902 IJCS 2019; 7(3): 122-127 © 2019 IJCS Received: 12-03-2019 Accepted: 03-04-2019

Bouchentouf Salim

 Faculty of Technology, Doctor Tahar Moulay University of Saida, Algeria
 Laboratory of Naturals products and Bioactives, Algeria

Allali Hocine

(2) Laboratory of Naturals products and Bioactives(3) Department of Chemistry, faculty of Sciences, Aboubekr Belkaid University of Tlemcen, Algeria

Ghalem Said

(2) Laboratory of Naturals products and Bioactives(3) Department of Chemistry, faculty of Sciences, Aboubekr Belkaid University of Tlemcen, Algeria

Missoum Noureddine

(2) Laboratory of Naturals products and Bioactives(3) Department of Chemistry, faculty of Sciences, Aboubekr Belkaid University of Tlemcen, Algeria

Correspondence Bouchentouf Salim (1) Faculty of Technology, Doctor Tahar Moulay University of Saida, Algeria (2) Laboratory of Naturals products and Bioactives, Algeria

Computational chemistry contribution in study of Terpenoid's from *Rosemary* and *Salvia* on diabetes type 2 treatment

Bouchentouf Salim, Allali Hocine, Ghalem Said and Missoum Noureddine

Abstract

Nowadays phytotherapy is important research subject over the world attracting researchers for less use of synthesized drugs because of their secondary effects. In this paper we use molecular modeling and molecular docking as tools for valorization of natural's plants in medicinal use which permit saving time and money in studying medicinal plants actions. We study anti-diabetic effect of main molecules from *Rosemary* and *Salvia* by investigating inhibition process of DPP-4 enzyme using Molecular Operating Environment software. Obtained results show importance of natural molecules from *Rosemary* and *Salvia* in diabetes type 2 treatment comparing to synthesized molecules used as drugs that have many secondary undesirables' effects.

Keywords: Diabetes type 2- phototherapy- DPP4 - Molecular modeling- medicinal plants

1. Introduction

Use of medicinal plants (phytotherapy) for diseases treatment is subject interesting researchers in many fields. Computational and theoretical chemistry (molecular modeling and molecular docking) allow saving time and money in drug discovering and conception and also contribute de better comprehension of medicinal plants action against diseases. Nowadays natural's terpenoids from medicinal plants as Rosemary and Salvia (Lamiaceae family) are widely investigated for their therapeutic effect (e.g. inflammatory pain) ^[1]. Most investigated terpenoids are Carsonic acid and Carnosol and many recent researches show efficacy of Carsonic acid and Carnosol against many illnesses (Table 1). Other recent researches show presence of diterpenoids and triterpenoids (figure 1) similar to carsonic acid and carnosol that may have positive effect on human health ^[2, 3]. Salvia spices is distributed all around the word, it is also consumed as tea and food in some Mediterranean region. Many Salvia and Rosemary spices are accepted as medicinal by Pharmacopeias (European Pharmacopeia and British Pharmacopeia)^[3]. Rosemary extracts were classified as food additives by the European Commission under E393 code ^[2]. Researches interest to carsonic acid and carnosol increase since U.S food Drug Administration and European food safety approved their use as food additive [4, 5, 6]. Analytical method showed high extraction yields for the determination of this compound in a complex matrix such as tissue.

Table 1	:(Carsonic	acid	and	Carsonol	effects
Table 1	: (Carsonic	acid	and	Carsonol	effect

Diseases / Pains	References
Antioxidant	11-13 A2
antimicrobial	14-17 A2
Antitumor	20-21 A2
Anti-inflammatory	22-24 A2
Anti-obesity	25-26 A2
Anticancer,	A 2 et petiwala
Anti-proliferative	A2
Anti-invasive	A2

Among investigated disease by computational chemistry we find Diabetes type 2. Type 2 diabetes (T2DM) is a metabolic disease which cause hyperglycaemia with pathophysiological factors and may bring about other health damage ^[7].

Main important enzyme responsible of type 2 Diabetes is Dipeptidyl-peptidase (DPP-4), which is also known as CD26 or 5TB4. The importance of DPP-4 for researchers raised since the approval of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus (T2DM) [25 article clove].




Fig 1: Terpenoids structures from Rosemary and Salvia

In best of our knowledge no studies have been done on inhibition of DPP-4 by extracted oils from *Rosemary* and *Salvia*. In this work we are going to study the anti-diabetic effect of some terpenoids from *Rosemary* and *Salvia* in inhibition of DPP-4 using molecular modeling and molecular docking. The Molecular Environment Operating software is used ^[8].

2. Materials and Methods

According to recent researches terpenoids from *Rosemary* and *Salvia* were identified ^[6], and their structures were downloading from PubChem Data Base (Figure 1]. The structure of Dipeptidyl-peptidase (DPP-4) (Figure 2) was downloading from PROTEIN DATA BANK (code 5T4B) with three-dimensional structure obtained by X-ray diffraction

(resolution 1.76 Å).




Fig 2: 3D DPP-4 structure

International Journal of Chemical Studies

2.2. Preparation and optimization of both enzyme and terpenoids from *Rosemary* and *Salvia*

The preparation of DPP-4 enzyme consists of elimination of one chain from the enzyme, than protonation and hiding hydrogen's of the second chain. Also energy minimizing of the enzyme and the geometry was performed using the field strengths in the MMFF94x and Hamiltonian AM1 implanted in MOE Software (Molecular Operating Environment). The second important step is isolation of the enzyme active site identification of general protein distribution (figure 3 and figure 4). The active site was performed using MOE site finder (according to MOE protocols). Main molecules from *Rosemary* and *Salvia* (figure 1) were downloading from PubChem Data base. Optimization of molecules was done under the same conditions of enzyme optimization.




Fig 3: Active site enzyme isolated




Fig 4: General Protein distribution

3. Docking and building complexes

After optimization of both molecules from *Rosemary* and *Salvia* (ligands) and enzyme, we proceed to positioning of ligands in to active site of the enzyme (5TB4) using Dock module (Molecular Docking) with MOE software (Molecular operating environment) ^[8]. The purpose of the Dock application is looking at favorable conformational binding between medium size ligands and a not so soft macromolecular target, which is usually a protein. The site

finder implemented in MOE used for prediction a nearby pocket or active site able to anchor molecule. Figure 5 shows Interaction potential in the optimized enzyme. Each level slider controls a contour graphic that shows the locations in space at which the probe has an interaction energy equal to given value (Kcal/mol). Energy balances of complexes are shown in table 2. In this work we are going to focus our study on interactions in three first complexes giving the best score.




Fig 5: Interaction Potential; N: Yellow, OH2: blue, DRY: Green

Molecules	Poses	Rmsd_refine	E_conf	E_place	E_refine	Score
Camosic acid 12-methyl ether	7	2.79107833	41.8281441	-58.2427597	-12.254199	-5.07837057
Camosic acid	9	2.71786642	19.5741119	-36.2673874	-12.5738926	-4.63349819
Camosol	8	1.40474367	73.8832932	-43.7374573	-12.466506	-4.5695734
Epirosmanol	8	2.92705584	69.0868988	-40.8612785	-12.6123352	-4.5118165
Erythrodiol	6	3.11756945	147.777985	-44.6511002	-12.8621216	-5.59761238
Ferruginol	6	1.15516746	63.946537	-63.2288437	-12.5733271	-5.3558712
Isorosmanol	9	2.7637105	91.5079956	-54.7710533	-13.3065596	-5.15827656
Manool	8	1.79628408	74.3825684	-47.5340347	-7.755373	-5.38269901
Rosmanol	9	2.84367108	75.288475	-52.3082123	-12.1775198	-4.44419193
Ursolic acid	9	1.84541321	77.215538	-50.3139153	-6.60194302	-5.44997978

rmsd_refine: the mean square deviation between the laying before refinement and after refinement pose, E_conf. energy conformer, E_place: score of the placement phase, E_scor1: score the first step of notation, E_refine: score refinement step and number of conformations generated by ligand. Score: the final score; is the score of the last step.

4. Results and discussion

Given results in table 2 show that complex formed with Erythrodiol gives the best score (-5.59761238 Kcal/mol), that mean the most stable complex. The second stable complex is

given with Ursolic acid ligand (-5.44997978 Kcal/mol). The third important score is given by Manool (-5.38269901 Kcal/mol).




Fig 6: Diagram interaction of Erythrodiol with DPP-4 enzyme

According to obtained results complex formed with Erythrodiol is the most stable (Figure 6), only one interaction is possible type H- π with distance of 3.74 Å and energy about -0.6 Kcal/mol. In the complex formed with Ursolic acid there

are no interactions, only Van Der Wals interactions are perceptible (figure 7).

The complex formed with Manool, there are no interactions only Van Der Wals interactions are perceptible (figure 8).




Fig 7: Diagram interaction of Ursolic acid with DPP-4 enzyme




Fig 8: Diagram Interaction of Manool with DPP-4 enzyme

Comparing to other researches ^[10] in the same field using molecular docking we find that there are synthesized molecules which inhibit DPP-4 enzyme better than molecules contained in *Rosemary and salvia* with score docking results not so higher than score obtained with Terpenoids from *Rosemary* and *Salvia*. The synthesized molecules (Metformin,

Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin) are used as drug for treatment of diabetes type 2, but those molecules have many secondary effects as repotted by European Medicines Agency ^[11]. The table 3 below gives an overview about secondary effect of principals synthesized hypoglycemic cited above.

Sitagliptin (Januvia) Blood and lymphatic system disorders Cardiac disorders Cardiac disorders Gastro intestinal disorders Respiratory, thoracic and mediastinal disorders Renal and urinary disorders Psychiatric disorders Linagliptin (Trajenta) Cardiac disorders Gastro intestinal disorders Gastro intestinal disorders Hepatobiliary disorders Gastro intestinal disorders Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Gastro intestinal disorders Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders Gastro intestinal disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Nervous system disorders Gastro intestinal disorders Saxagliptin (Onglyza) Cardiac disorders	Synthesized hypoglycemic	Secondary effect
Gastro intestinal disorders Nervous system disorders Respiratory, thoracic and mediastinal disorders Renal and urinary disorders Psychiatric disorders Cardiac disorders Gastro intestinal disorders Inagliptin (Trajenta) Cardiac disorders Gastro intestinal disorders Hepatobiliary disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Renal and urinary disorders Renal and urinary disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders General disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders	Sitagliptin (Januvia)	 Blood and lymphatic system disorders
 Nervous system disorders Respiratory, thoracic and mediastinal disorders Renal and urinary disorders Psychiatric disorders Cardiac disorders Gastro intestinal disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Gastro intestinal disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Gastro intestinal disorders Schin and subcutaneous tissue disorders Gastro intestinal disorders General disorders Gastro intestinal disorders General disorders General disorders General disorders Nervous system disorders Renal and urinary disorders Seasagliptin (Onglyza) Cardiac disorders Eye disorders 		 Cardiac disorders
• Respiratory, thoracic and mediastinal disorders • Renal and urinary disorders • Psychiatric disorders • Cardiac disorders • Gastro intestinal disorders • Hepatobiliary disorders • Metabolism and nutrition disorders • Nervous system disorders • Skin and subcutaneous tissue disorders • Renal and urinary disorders • Metformin (Glucophage) • Cardiac disorders • Gastro intestinal disorders • Gastro intestinal disorders • Gastro intestinal disorders • General disorder and administration site disorders • Injury, poisoning and procedural complication • Metabolism and nutrition disorders • Renal and urinary disorders • Nervous system disorders • Saxagliptin (Onglyza)		 Gastro intestinal disorders
 Renal and urinary disorders Psychiatric disorders Cardiac disorders Gastro intestinal disorders Hepatobiliary disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Cardiac disorders Skin and subcutaneous tissue disorders Gastro intestinal disorders Cardiac disorders Skin and subcutaneous tissue disorders General and urinary disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders General disorders General disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Nervous system disorders Renal and urinary disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders 		 Nervous system disorders
Psychiatric disorders Linagliptin (Trajenta) Cardiac disorders Gastro intestinal disorders Gastro intestinal disorders Hepatobiliary disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders General disorder and administration site disorders General disorders Nervous system disorders Nervous system disorders Netabolism and nutrition disorders Nervous system disorders Saxagliptin (Onglyza) Cardiac disorders		 Respiratory, thoracic and mediastinal disorders
Linagliptin (Trajenta) • Cardiac disorders Gastro intestinal disorders • Gastro intestinal disorders Hepatobiliary disorders • Metabolism and nutrition disorders Nervous system disorders • Nervous system disorders Skin and subcutaneous tissue disorders • Renal and urinary disorders Metformin (Glucophage) • Cardiac disorders • Gastro intestinal disorders • Gastro intestinal disorders • Gastro intestinal disorders • Gastro intestinal disorders • Gastro intestinal disorders • General disorders • General disorder and administration site disorders • Injury, poisoning and procedural complication • Metabolism and nutrition disorders • Nervous system disorders • Nervous system disorders • Vascular disorders		 Renal and urinary disorders
 Gastro intestinal disorders Hepatobiliary disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders Gastro intestinal disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Nervous system disorders Vascular disorders Vascular disorders Eye disorders 		 Psychiatric disorders
 Hepatobiliary disorders Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Renal and urinary disorders Cardiac disorders Ganeral disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Vascular disorders Eye disorders 	Linagliptin (Trajenta)	 Cardiac disorders
 Metabolism and nutrition disorders Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Cardiac disorders Gatro intestinal disorders Gatro intestinal disorders Renal and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Vascular disorders Eye disorders 		 Gastro intestinal disorders
 Nervous system disorders Skin and subcutaneous tissue disorders Renal and urinary disorders Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Saxagliptin (Onglyza) Cardiac disorders 		 Hepatobiliary disorders
Skin and subcutaneous tissue disorders Renal and urinary disorders Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Vascular disorders Eye disorders Eye disorders		 Metabolism and nutrition disorders
Renal and urinary disorders Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders		 Nervous system disorders
Metformin (Glucophage) Cardiac disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders Eye disorders		 Skin and subcutaneous tissue disorders
Gastro intestinal disorders Gastro intestinal disorders General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders		 Renal and urinary disorders
 General disorder and administration site disorders Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders 	Metformin (Glucophage)	 Cardiac disorders
 Injury, poisoning and procedural complication Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders 		 Gastro intestinal disorders
Metabolism and nutrition disorders Nervous system disorders Renal and urinary disorders Vascular disorders Cardiac disorders Eye disorders Eye disorders		 General disorder and administration site disorders
Nervous system disorders Renal and urinary disorders Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders		 Injury, poisoning and procedural complication
Renal and urinary disorders Vascular disorders Cardiac disorders Eye disorders Eye disorders		 Metabolism and nutrition disorders
Vascular disorders Saxagliptin (Onglyza) Cardiac disorders Eye disorders		 Nervous system disorders
Saxagliptin (Onglyza) Cardiac disorders Eye disorders		 Renal and urinary disorders
 Eye disorders 		 Vascular disorders
	Saxagliptin (Onglyza)	 Cardiac disorders
		 Eye disorders
Gastro intestinal disorders		 Gastro intestinal disorders

Table 3: Main secondary effect of some synthesized hypoglycemic [11]

~ 126 ~

	 Infections and infestations Injury, poisoning and procedural complications Psychiatric disorders Musculoskeletal and connective tissue disorders Hepatobiliary disorders Vascular disorders Renal and urinary disorders
Vildagliptin (Galvus)	 Blood and lymphatic system disorders Cardiac disorders Gastro intestinal disorders Eye disorders General disorder and administration site disorders Hepatobiliary disorders Immune system disorders Hepatobiliary disorders Metabolism and nutrition disorders Psychiatric disorders Renal and urinary disorders Respiratory, thoracic and mediastinal disorders Skin and subcutaneous tissue disorders Vascular disorders

5. Conclusion

Regarding the obtained results we can admit that *Rosemary* and Salvia have significant effect on DPP-4 enzyme inhibition and consequently anti-diabetic effect without mentioned undesirable secondary effect on Health. Also we can conclude that molecular modeling and molecular docking methods allow discovering new molecules from plants that may have therapeutic effect. Computational chemistry is very important for phytotherapy research allowing saving time and money permitting identification molecules with therapeutic interest. In this way we encourage investigating *Rosemary* and *Salvia* in diabetes type 2 treatments.

References

- 1. Maione F, Cantone V, Pace S, Chini MG, Bisio A, Romussi G, *et al.* Anti-inflammatory and analgesic activity of carnosol and carnosic acid *in vivo* and *in vitro* and *in silico* analysis of their target interactions. British Journal of Pharmacology 2016. DOI: 10.1111/bph.13545.
- 2. Simona Birtic, Pierre Dussort, Francois-Xavier Pierre, Antoine C. Bily, Marc Roller, carnosic acid, Phytochemistry 2015;115:9-19.
 - http://dx.doi.org/10.1016/j.phytochem.2014.12.026
- Gulatci Topcu, Mehmet Ozturk, Tuba Kusman, Ayse Ash Barla Demirkoz, Ufuk Kolak, Ayhan Ulubelen; Terpenoids, essential oil composition, fatty acid pro_le, and biological activities of Anatolian *Salvia fruticosa* Mill, Turk J Chem 2013;37:619-632. DOI:10.3906/kim-1303-25
- Borrás-Linares I, Stojanovi´c Z, Quirantes-Piné R, Arráez-Román D, Švarc-Gaji´c J, Fernández-Gutiérrez A *et al.* Rosmarinus officinalis leaves as a natural source of bioactive compounds. Int. J. Mol. Sci 2014;15:20585-20606.
- 5. Aguilar F, Autrup H, Barlow S, Castle L, Crebelli R, Dekant W *et al.* Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) on a request related to. EFSA J 2008;628-633, 1-19.
- Andrea del Pilar Sánchez-Camargo, Virginia García-Cañas, Miguel Herrero, Alejandro Cifuentes and Elena Ibáñez, Comparative Study of Green Sub- and Supercritical Processes to Obtain Carnosic Acid and Carnosol-Enriched *Rosemary* Extracts with in Vitro Anti-

Proliferative Activity on Colon Cancer Cells, Int. J. Mol. Sci. 2016, 17, 2046; doi:10.3390/ijms17122046

- 7. Grimaldi A. La sante ecartelee Entre sante publique et business, Dialogues 2013,220.
- 8. Shukri R, Mohamed S, Mustapha NM. Cloves protect the heart, liver and lens of diabetic rats, Food Chemistry 2010,1116-1121.

DOI: dx.doi.org/10.1016/j.foodchem.2010.03.094.

- 9. Molecular Operating Environment (MOE), Chemical Computing Group, Montreal, Quebec, Canada 2013.
- Hicham Ayachi, Shirin Jamshidi, Meriem Merad, Yassine Bendiabdallah, Said Ghalem, Khondaker Miraz Rahman. Design of New Inhibitors of Dipeptidyl Peptidase-4 in Type 2 Diabetes by Computer Simulations, Der Pharma Chemica 2017;9(2):17-29.
- 11. European Medicines Agency, Science medicine Health, Eudra Vigilance.